ImmunologybioRxiv
The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration.
D. Kim, S.-H. Lee, Y.-H. Choi…·A. Debin
This paper evaluates Nexavant, a TLR3 agonist, showing enhanced anti-cancer effects and synergy with anti-PD-1 therapy through immune cell infiltration.
DOI 10.3390/cancers15245752